Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer

In recent years, immune checkpoint inhibitors (ICIs) have made breakthroughs in the field of lung cancer and have become a focal point for research. Programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor monotherapy was the first to break the treatment pattern for non-small cell lu...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Ying, Li, Hui, Zhang, Liang, Liu, Jing-Jing, Yang, Chang-Liang, Zhang, Shuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367026/
https://www.ncbi.nlm.nih.gov/pubmed/34133356
http://dx.doi.org/10.1097/CM9.0000000000001560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367026/
https://www.ncbi.nlm.nih.gov/pubmed/34133356
http://dx.doi.org/10.1097/CM9.0000000000001560

Ejemplares similares